Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models by SHOEMAKER, Alex R, MITTEN, Michael J, BAUCH, Joy, MARSH, Kennan, TAHIR, Steven K, XIUFENYANG, TSE, Christin, FESIK, Stephen W, ROSENBERG, Saul H, ELMORE, Steven W, ADICKES, Jessica, ACKLER, Scott, REFICI, Marion, FERGUSON, Debra, OLEKSIJEW, Anatol, O'CONNOR, Jacqueline M, BAOLE WANG, FROST, David J

Get full text

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo by Ackler, Scott, Mitten, Michael J., Foster, Kelly, Oleksijew, Anatol, Refici, Marion, Tahir, Stephen K., Xiao, Yu, Tse, Christin, Frost, David J., Fesik, Stephen W., Rosenberg, Saul H., Elmore, Steven W., Shoemaker, Alexander R.

Get full text

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo by Ackler, Scott, Xiao, Yu, Mitten, Michael J, Foster, Kelly, Oleksijew, Anatol, Refici, Marion, Schlessinger, Sally, Wang, Baole, Chemburkar, Sanjay R, Bauch, Joy, Tse, Christin, Frost, David J, Fesik, Stephen W, Rosenberg, Saul H, Elmore, Steven W, Shoemaker, Alex R

Get full text

Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models by Ferguson, Debra, Rodriguez, Luis E, Palma, Joann P, Refici, Marion, Jarvis, Kenneth, O'Connor, Jacqueline, Sullivan, Gerard M, Frost, David, Marsh, Kennan, Bauch, Joy, Zhang, Haiying, Lin, Nan-Horng, Rosenberg, Saul, Sham, Hing L, Joseph, Ingrid B J K

Get full text

Abstract 5339: BCL2A1 is expressed in myelofibrosis specimens and JAK2-mutated UKE-1 cells, yet does not inhibit synergistic cell killing by BCL-XL inhibitor navitoclax plus JAK1/2... by Refici, Marion, Yang, Ziping, Riehm, Jacob, Phillips, Darren, Souers, Andrew, Harb, Jason

Get full text

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer by Hussain, Maha, Carducci, Michael A., Slovin, Susan, Cetnar, Jeremy, Qian, Jiang, McKeegan, Evelyn M., Refici-Buhr, Marion, Chyla, Brenda, Shepherd, Stacie P., Giranda, Vincent L., Alumkal, Joshi J.

Get full text

FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model by Mudd, Sarah R., Voorbach, Martin J., Reuter, David R., Tapang, Paul, Hickson, Jonathan A., Refici-Buhr, Marion, Fox, Gerard B., Albert, Daniel H., Luo, Yanping, Day, Mark

Get full text

Fcγ-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-α levels by Refici, Marion L., Metzger, Dennis W., Arulanandam, Bernard P., Lennartz, Michelle R., Loegering, Daniel J.

Get full text

Fcgamma-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-alpha levels by Refici, Marion L, Metzger, Dennis W, Arulanandam, Bernard P, Lennartz, Michelle R, Loegering, Daniel J

Get full text

Fcγ-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-α levels by REFICI, Marion L, METZGER, Dennis W, ARULANANDAM, Bernard P, LENNARTZ, Michelle R, LOEGERING, Daniel J

Get full text

Fc{gamma}-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-{alpha} levels by Refici, Marion L, Metzger, Dennis W, Arulanandam, Bernard P, Lennartz, Michelle R, Loegering, Daniel J

Get full text